GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » EBIT

Arix Bioscience (LSE:ARIX) EBIT : £-5.89 Mil (TTM As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Arix Bioscience EBIT?

Arix Bioscience's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was £-2.96 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was £-5.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Arix Bioscience's annualized ROC % for the quarter that ended in Jun. 2023 was -4.87%. Arix Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -734.24%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Arix Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -7.12%.

Arix Bioscience EBIT Historical Data

The historical data trend for Arix Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arix Bioscience EBIT Chart

Arix Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial -13.70 -11.99 -7.31 -4.46 -5.29

Arix Bioscience Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.00 -2.47 -2.36 -2.93 -2.96

Competitive Comparison of Arix Bioscience's EBIT

For the Biotechnology subindustry, Arix Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arix Bioscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arix Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Arix Bioscience's EV-to-EBIT falls into.


Arix Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-5.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arix Bioscience  (LSE:ARIX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Arix Bioscience's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-5.918 * ( 1 - 0% )/( (104.892 + 138.169)/ 2 )
=-5.918/121.5305
=-4.87 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=227.847 - 0.173 - ( 122.782 - max(0, 1.923 - 125+122.782))
=104.892

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=240.534 - 1.377 - ( 100.988 - max(0, 1.414 - 103.365+100.988))
=138.169

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Arix Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.918/( ( (0.168 + max(0.354, 0)) + (0.09 + max(1, 0)) )/ 2 )
=-5.918/( ( 0.522 + 1.09 )/ 2 )
=-5.918/0.806
=-734.24 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.98 + 0 + 0.238) - (0.173 + 0 + 1.691)
=0.354

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.377) - (1.377 + 0 + 0)
=1

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Arix Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=-5.892/82.782
=-7.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arix Bioscience EBIT Related Terms

Thank you for viewing the detailed overview of Arix Bioscience's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Arix Bioscience (LSE:ARIX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » EBIT
Comparable Companies
LSE:HVO LSE:FARN LSE:BVXP LSE:SCLP LSE:OXB LSE:FUM LSE:REDX LSE:OBD LSE:4BB LSE:ETX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
50 Duke Street, Duke Street House, London, GBR, W1K 6JL
Website
https://www.arixbioscience.com
Arix Bioscience PLC is a healthcare and life science company. Its business model is to source, finance, and develop healthcare and life science businesses that deliver or seek to deliver therapies to patients. Its segment includes sourcing, financing, and developing healthcare and life science businesses globally.

Arix Bioscience (LSE:ARIX) Headlines

No Headlines